DOI: http://dx.doi.org/10.18203/2320-6012.ijrms20185394

Role of non-lipid risk factors like hs-CRP, uric acid and thyroid stimulating hormone in metabolic syndrome

V. Srinivasa Babu, C. Ramaswamy, V. Kalyan Chakravarthy

Abstract


Background: Metabolic syndrome is the cluster of diseases which arises due to excess of plasma glucose, cholesterol, fatty acids, blood pressure and obesity. The role of lipids in the development of MetS had been extensively studied. Though some non-lipid factors like hsCRP, uric acid and TSH level also remain elevated in the serum of the MetS patients, the role of these non-lipid risk factors remain incompletely understood. The objective of this study was to investigate which of these factors better predicts Mets, in order to help prevention and early detection of MetS and its associated type 2 diabetes mellitus and cardiovascular diseases. Aim and objectives was to study the significance of serum highly sensitive C-reactive protein (hs-CRP), serum uric acid (SUA) and thyroid stimulating hormone (TSH) levels in metabolic syndrome.

Methods: A total of four hundred and fifty subjects (211 men and 239 women) aged ≥35 years attending the hospital were divided into three groups based on the components level of MetS as control (CS), normal (MS) and severe (SMS) MetS groups. Their fasting blood sample were taken and analyzed for the serum hs-CRP, uric acid and TSH levels. The result showed that the mean hs-CRP and uric acid levels were significantly higher in Metabolic Syndrome group (MS) and in Severe Metabolic Syndrome group (SMS) when compared to control group. But the mean TSH levels were more in MS group and in SMS group than the control which was statistically not significant. The analysis of relative significance of these risk factors showed that serum hs-CRP level had a positive linear correlation with the severity of MetS whereas, the TSH level was significantly high only in SMS and the uric acid level was not correlated with the MetS.

Results: Our study revealed that type II (absence of sutural bones) was commoner than type I (presence of type I) asterion. The asterion was 4.82±0.58 cm from tip of the mastoid process on the right side and 4.70±0.70 cm on the left. It was greater in males than in females, p value being statistically significant (P = 0.00 and P = 0.02 for right and left sides respectively). The distance of asterion from supramastoid crest was 4.22±0.73 cm on the right and 4.23±0.58 cm on the left. The distance in males was more than in females. The P value 0.00 was statistically significant on the right side. Regarding the position of the asterion in relation to transverse sinus, it was on the transverse sinus in 62% cases, below it in 32% and above in 6%.

Conclusions: In the present study, there was higher mean serum hs-CRP level in patients with metabolic syndrome which showed a linear increase with increasing number of components of the metabolic syndrome. Though available literature indicated that hyperuricemia adult subjects tend to develop MetS more frequently our findings showed this increase was not dependent on the severity of MetS. Also, significantly high TSH levels were found only in severe MetS suggest that as per this study the serum hs-CRP values may be consider as the diagnostic criteria for metabolic syndrome and helps to improve future prediction of development of type 2 DM and cardiovascular diseases.


Keywords


hs-CRP, Metabolic syndrome, Non-lipid risks, Uric acid and TSH

Full Text:

PDF

References


Balkau B, Valensi P, Eschwège E, Slama G. A review of the metabolic syndrome. Diabetes Metab. 2007;33:405-13.

Kodama S, Saito K, Yachi Y, Asumi M, Sugawara A, Totsuka K, Saito A, Sone H. The association between serum uric acid and development of type 2 diabetes mellitus. A Meta-Analysis. Diabetes care. 2009 Jun 23.

Lv Q, Meng XF, He FF, Chen S, Su H, Xiong J, et al. High serum uric acid and increased risk of type 2 diabetes: a systemic review and meta-analysis of prospective cohort studies. PloS one. 2013 Feb 20;8(2):e56864.

DeBosch BJ, Kluth O, Fujiwara H, Schurmann A, Moley K. Earlyonset metabolic syndrome in mice lacking the intestinal uric acid transporter SLC2A9. Nat Commun. 2014;5:4642.

Facchini F, Chen YD, Hollenbeck CB, Reaven GM. Relationship between resistance to insulin-mediated glucose uptake, urinary uric acid clearance, and plasma uric acid concentration. JAMA. 1991;266:3008-11.

Haffner SM. The metabolic syndrome: inflammation, diabetes mellitus, and cardiovascular disease. Am J Cardiol. 2006;97(2A):3A-11A.

Frohlich M, Imhof A, Berg G, Hutchinson WL, Pepys MB, Boeing H, et al. Association between C-reactive protein and features of the metabolic syndrome: a population-based study. Diabetes Care. 2000;23(12):1835-9.

Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia. 1997;40(11):1286-92.

Kokkoris P, Pi-Sunyer FX. Obesity and endocrine disease. Endocrinology and Metabolism Clinics of North America. 2003;32:895-914.

Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009 Oct 20;120(16):1640-5.

Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, et al. Harmonizing the metabolic syndrome: a joint interim statement of the international diabetes federation task force on epidemiology and prevention; national heart, lung, and blood institute; American heart association; world heart federation; international atherosclerosis society; and international association for the study of obesity. Circulation. 2009 Oct 20;120(16):1640-5.

Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation. 2005 Oct 25;112(17):2735-52.

WHO. World Health Organization (WHO) Expert Consultation: Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363(9403):157-63.

WHO. World Health Organization (WHO). Waist Circumference and Waist-Hip Ratio Report of a WHO Expert Consultation. 2008;1-39.

Burtis CA, Bruns DE. Text book of Tietz fundamentals of clinical chemistry and molecular diagnostics, seventh edition, Elsevier Inc.; 2015:374,420,819.

Reaven GM. Banting lecture 1988. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-607.

Vidyasagar S, Abdul razak UK, Prashanth CK, Varma DM, Bairy KL. Highly sensitive C reactive protein in metabolic syndrome. JIACM. 2013;14:230-4.

Gowdaiah PK, Mamatha TR, Nirgude D, Hosamani PB. High sensitivity C-reactive protein in metabolic syndrome.Int J Adv Med. 2016;3:607-10.

Bo S, Gentile L, Ciccone G, Baldi C, Benini L, Dusio F, et al. The metabolic syndrome and high c reactive protein: prevelance and difference by sex in a southern European population based cohort. Diabetes Metab Res Rev. 2005;21;515-24.

Mahajana A, Jaiswala A, Tabassum R, Podder A, Ghosh S, Madhu SV, et al. Elevated levels of Creactive protein as a risk factor for Metabolic Syndrome in India. Atherosclerosis. 2012;220:275-81.

Woo J, Swaminathan R, Cockram C, Lau E, Chan A. Association between serum uric acid and some cardiovascular risk factors in a Chinese population. Postgrad Med J. 1994;70:486-91.

Laws A, Reaven GM. Evidence for an independent relationship between insuline resistance and fasting plasma HDL. Cholesterol, triglyceride and insulin concentration. J Intern Med. 1992;231:25-30.

Cicero AF, Fogacci F, Giovannini M, Grandi E, Rosticci M, D’Addato S, et al. Serum uric acid predicts incident metabolic syndrome in the elderly in an analysis of the Brisighella Heart Study. Scientific reports. 2018 Aug 1;8(1):11529.

Yuan H, Yu C, Li X, Sun L, Zhu X, Zhao C, et al. Serum uric acid levels and risk of metabolic syndrome: a dose-response meta-analysis of prospective studies. J Cli Endocrinol Metab. 2015 Nov 1;100(11):4198-207.

Ford ES, Li C, Cook S, Choi HK. Serum concentrations of uric acid and the metabolic syndrome among US children and adolescents. Circulation. 2007 May 15;115(19):2526-32.

Lee YK, Kim JE, Oh HJ, Park KS, Kim SK, Park SW, et al. Serum TSH level in healthy Koreans and the association of TSH with serum lipid concentration and metabolic syndrome. Kor J Int Med. 2011 Dec;26(4):432.